• About
  • Subscribe
  • Advertise
  • Contact
Friday, June 13, 2025
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home Ophthalmic insights Research

New eye models allow for better drug development

by Callum Glennen
December 30, 2019
in Ophthalmology, Research
Reading Time: 2 mins read
A A
The repigmentation of RPE Cells. Image credit: Mika Reinisalo

The repigmentation of RPE Cells. Image credit: Mika Reinisalo

Share on FacebookShare on Twitter

A newly detailed model for cultivating retinal pigment cells could make the development of new and improved ocular drugs significantly easier.

Developed by researchers from the University of Eastern Finland, the new model allows for cultivated retinal pigment epithelial cell lines to feature both pigmentation and a blood-retinal barrier. These qualities provide a much more accurate representation of the back of the eye, allowing for new drugs to be more thoroughly tested.

Drugs tend to bind to cellular pigment and, consequently, accumulate in the retinal pigment epithelium (RPE). Not only does the new model allow this effect to be studied in more detail, but non-pigmented RPE cells can also be re-pigmented by feeding them melanin.

This lets the rate at which drugs bind to melanin to be compared between samples.

“By using non-pigmented cells as controls, we were able to study how much of a drug given to the cells eventually ends up in the melanosomes,” Dr Mika Reinisalo, from the University of Eastern Finland, said.

“Next, we need to find out for how long the melanosomes can hold on to a drug, and whether this causes any harm. The accumulation of drugs in the melanosomes can, on the other hand, make it possible to target drugs at specific tissues.”

This adds to another model detailed by the University of Eastern Finland earlier this year that features a more realistic blood-retinal barrier than current models.

As the blood-retinal barrier affects both the entry and exit of drugs from the eye, simulating it is important in the early stages of drug development. In a study published in Pharmaceuticals earlier this year, the team identified a new RPE cell population that forms a layer that resembles the epithelial layer of the eye.

“We named this cell population after its discoverer, Senior Laboratory Technician Lea Pirskanen, who is also one of the authors of the study,” Dr Laura Hellinen, from the University of Eastern Finland, said.

“These cells are now known as LEPI cells. We decided to study them in more detail and discovered that in comparison to earlier cell models, LEPI cells are better differentiated and they form a tighter and more realistic barrier through which drugs have to pass.”

It is hoped the new models will allow for a reduction in the need for animal testing.

Tags: labresearchRetinal Pigment Cellsretinitis pigmentosaUniversity of Eastern Finland

Related Posts

Researchers believe a simple eye scan will in future reveal if a person has other health issues throughout their bodies. Image: Nadiia/stock.adobe.com.

An eye scan for various diseases? CERA is looking into it

by By Allison Harding
June 12, 2025

Can you imagine reporting for surgery and having an eye scan at the front desk that can reveal if you...

New research on a drug to tackle diabetic retinopahty suggests clinicians should prioritise stability of glycemia, not just lowering blood sugar. Image: nazif/stock.adobe.com.

Research shows promise in drug to tackle diabetic retinopathy

by Staff Writer
June 9, 2025

Researchers in the US are developing an experimental drug to slow or halt damage to the eye from diabetic retinopathy....

A number of international studies into RLRL technology have been reporting back with their findings. Image: Eyerising International.

Studies show growing momentum for red-light technology

by Staff Writer
June 5, 2025

The first Australian data into the efficacy of repeated low-level red-light (RLRL) has been published in what is shaping to...

Join our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited